ESG Report 2024

The product development efforts of the Group strictly complies with national pharmaceutical laws, regulations and technical guidelines. The research team combines the technical requirements for drug registration and the consistency evaluation of generic drugs to conduct thorough studies on the pharmaceutical quality and bioequivalence of the products. This ensures that the drugs meet the requirements for safety, efficacy, and quality control. During the Year, the following products of the Group passed the generic drug quality and efficacy consistency evaluation, including: Injectable Imipenem and Cilastatin Sodium (Specifications: 0.5g; 1.0g), Amoxicillin and Clavulanate Potassium Tablets (Specification: 0.375g), Injectable Cefuroxime Sodium (Specifications: 0.75g, 1.5g), Injectable Ceftazidime (Specification: 1.0g), Amoxicillin Granules (Specification: 0.125g) and Mupirocin Ointment (Specification: 2% (5g:0.1g)). The approval of these products in the generic drug consistency evaluation has further enhanced the competitiveness of Group in the market. As of this year, the Group has accumulated 24 products that have passed (including deemed to have passed) the consistency evaluation. The Group will continue to promote the generic drug consistency evaluation work to provide patients with more high-quality medication options. the Cyclosporin is a selective immunosuppressant that reduces inflammation and allergic reactions by inhibiting T-lymphocyte activation upon antigen stimulation and suppressing the antigen-presenting function of the skin immune system. It is indicated for the treatment of canine chronic atopic dermatitis and feline chronic allergic dermatitis. Cyclosporin Oral Solution "Bongpitan" Approved as National Class V New Veterinary Drug Animal Healthcare 27 Enhancing Medical Accessibility 6.2 The Group's business covers pharmaceutical finished products, active pharmaceutical ingredients (APIs), and intermediates, with product pipeline in the fields of endocrine, metabolism, autoimmune, opthalmic, anti-infection, etc. Animal Healthcare Products Intermediates & APIs 6-APA T-Octylammonium clavulanate Penicillin G potassium first crystal Intermediates APIs Semi-synthetic penicillins type Cephalosporins type β-lactamase inhibitors type Carbapenems type Human Pharmaceuticals Antibiotics Diabetes drugs Antiallergic drugs Antiviral drugs Cold/cough suppressants Livestock drugs Poultry drugs Pet drugs Aquatic drugs Consistency Evaluation of Generic Drugs Environmental, Social and Governance Report 2024 The United Laboratories International Holdings Limited Ophthalmic drugs Skin drugs for external use Cardiovascular and cerebrovvascular drugs Nervous system drugs, etc Healthcare products, etc